hotspot
As a boy growing up with hemophilia A, Noah Frederick reserved the end of his annual checkups to talk about new technologies. His doctor walked through various experimental approaches for the bleeding disorder and, invariably, gene therapy. It was coming, he always said, in your lifetime.
Last year, it finally arrived. But Frederick, now a 23-year-old software engineer, isn’t sure he’ll get it. He wants to be part of the sci-fi future gene therapy has always represented, but a recent doctor’s visit left him uncertain.
advertisement
“I’m on the fence,” he said.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Patient advocates debate FDA's accelerated approval process
Next article： How to save PrEP access — and even expand it
Next article： How to save PrEP access — and even expand it
